This 2014 study investigates the potential synergistic effects of combining high-dose intravenous ascorbic acid (vitamin C) with interleukin-2 (IL-2) immunotherapy in cancer treatment. The authors discuss how ascorbic acid may enhance the efficacy of IL-2 by modulating immune responses, reducing oxidative stress, and improving patient tolerance to therapy. Preliminary findings
